Edward J. Rapp
Edward J. Rapp's purchase track record
Edward J. Rapp has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/30/2022 | XOS | $207K | +11.3% | -34.7% | +2.4% |
| 11/18/2021 | XOS | $427K | -45.8% | -38.7% | -17.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.
Transaction History
| XOS | ▲ Buy | Grant | 2,670 | $0 | 7/10/2026 | View on chart |
| XOS | ▲ Buy | Grant | 60,584 | $0 | 7/10/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 1,118 | $0 | 5/8/2026 | View on chart |
| XOS | ▲ Buy | Grant | 5,182 | $0 | 4/10/2026 | View on chart |
| XOS | ▲ Buy | Grant | 2,401 | $0 | 1/10/2026 | View on chart |
| XOS | ▲ Buy | Grant | 1,883 | $0 | 10/10/2025 | View on chart |
| XOS | ▲ Buy | Grant | 62,377 | $0 | 7/10/2025 | View on chart |
| XOS | ▲ Buy | Grant | 1,601 | $0 | 7/10/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 1,203 | $0 | 5/9/2025 | View on chart |
| XOS | ▲ Buy | Grant | 1,407 | $0 | 4/10/2025 | View on chart |
| XOS | ▲ Buy | Grant | 1,065 | $0 | 1/10/2025 | View on chart |
| XOS | ▲ Buy | Grant | 1,065 | $0 | 10/10/2024 | View on chart |
| XOS | ▲ Buy | Grant | 28,694 | $0 | 7/10/2024 | View on chart |
| XOS | ▲ Buy | Grant | 717 | $0 | 7/10/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 1,322 | $0 | 5/3/2024 | View on chart |
| XOS | ▲ Buy | Grant | 445 | $0 | 4/10/2024 | View on chart |
| XOS | ▲ Buy | Grant | 650 | $0 | 1/15/2024 | View on chart |
| XOS | ▲ Buy | Grant | 15,151 | $0 | 10/10/2023 | View on chart |
| XOS | ▲ Buy | Grant | 15,151 | $0 | 7/12/2023 | View on chart |
| XOS | ▲ Buy | Grant | 444,444 | $0 | 6/12/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 1,450 | $0 | 5/5/2023 | View on chart |
| XOS | ▲ Buy | Grant | 7,936 | $0 | 4/3/2023 | View on chart |
| XOS | ▲ Buy | Grant | 7,936 | $0 | 1/10/2023 | View on chart |
| XOS | ▲ Buy | Open Market | 300,000 | $207K | 11/30/2022 | View on chart |
| XOS | ▲ Buy | Grant | 3,378 | $0 | 9/30/2022 | View on chart |
| XOS | ▲ Buy | Grant | 115,606 | $0 | 9/12/2022 | View on chart |
| XOS | ▲ Buy | Grant | 3,816 | $0 | 8/3/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 1,421 | $0 | 5/6/2022 | View on chart |
| XOS | ▲ Buy | Grant | 1,474 | $0 | 12/31/2021 | View on chart |
| XOS | ▲ Buy | Open Market | 100,000 | $427K | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
XOS Included in Weekly Industrials Movers List
Xos Inc. was listed among industrials stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an analyst target of $4.00. The high_beta signal suggests the stock may experience larger price swings than the broader market.
XOS Included in Weekly Industrials Movers List. Xos Inc. was listed among industrials stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an analyst target of $4.00. The high_beta signal suggests the stock may experience larger price swings than the broader market.